Correction to: Nature Reviews Endocrinology https://doi.org/10.1038/s41574-024-00979-9, published online 17 April 2024
In the version of the article initially published, in the “GLP1RAs and cardiorenal risk” section, the sentence now reading “A dedicated trial studying the effects of weekly 1 mg semaglutide on renal outcomes …” originally read “2.4 mg semaglutide” and has now been amended in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ansari, S., Khoo, B. & Tan, T. Author Correction: Targeting the incretin system in obesity and type 2 diabetes mellitus. Nat Rev Endocrinol (2024). https://doi.org/10.1038/s41574-024-00997-7
Published:
DOI: https://doi.org/10.1038/s41574-024-00997-7
